Merck and Moderna cancer vaccine reduces melanoma death or recurrence risk by 42%, but shares decline

Source Summary

A cancer vaccine developed jointly by Merck and Moderna demonstrated a 42% reduction in melanoma death or recurrence risk in clinical results. Despite the positive efficacy data, shares of both companies fell following the announcement.

Why it matters

The vaccine represents a potential new treatment option for melanoma patients, though the market's negative reaction suggests investor concerns about commercial viability or competitive positioning.

Read the Source

• Investing.com ↗